Results 111 to 120 of about 12,862 (201)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

ClinicoEconomics and Outcomes Research, 2015
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat ...
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V   +4 more
doaj  

Barrier-independent, fitness-associated differences in sofosbuvir efficacy against hepatitis c virus

, 2017
Sofosbuvir displays a high phenotypic barrier to resistance, and it is a component of several combination therapies for hepatitis C virus (HCV) infections.
Moreno, Elena, Rice, Charles M., Gregori, Josep Maria, Gallego, Isabel, Domingo, Esteban, Sheldon, Julie, Perales, Celia, Esteban, Juan Ignacio   +7 more
core   +1 more source

Sofosbuvir, a new nucleotide analogue, for the treatment of chronic hepatitis C infection

, 2015
Objective: To evaluate the clinical role of sofosbuvir (Solvadi) in the treatment of hepatitis C virus (HCV). Data Sources: A MEDLINE, EMBASE, and Cochrane search indexed from January 2000 to July 2014 was performed using the search terms GS-7977 and ...
Yancey, Abigail, Armbruster, Anastasia, Tackett, Stephanie   +2 more
core   +1 more source

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with ...
Kwo, Paul Y., Agarwal, Kosh, Muir, Andrew J., Buti, Maria, Symonds, William T., Mo, Hongmei, Afdhal, Nezam, Jacobson, Ira M., Marcellin, Patrick, Pang, Philip S., Foster, Graham R., Mangia, Alessandra, Chojkier, Mario, Ding, Xiao, Romero Gomez, Manuel, Yang, Jenny C., Zarski, Jean Pierre, Bräu, Norbert, Gitlin, Norman, Puoti, Massimo, Buggisch, Peter, Forns, Xavier, Subramanian, G.Mani, Zeuzem, Stefan, McHutchison, John G.   +24 more
core  

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj  

Molnupiravir is effective against hepatitis E virus infection in an animal model. [PDF]

Hepatol Commun
Wu S, Chew NF, Ma X, Situ J, Shun EH, Li C, Ip JD, Ho SS, Zhang AJ, Tsoi JY, Chan WM, Ma W, Liang Y, Mao W, Chen KWY, Yin F, To KK, Yuan S, Chan JF, Zhu L, Huang Y, Sridhar S.   +21 more
europepmc   +1 more source

Real-world Effectiveness and Safety of Coblopasvir plus Sofosbuvir in the Treatment of Chronic Hepatitis C Infection in Wenzhou, Eastern China: A Multicenter Observational Study. [PDF]

J Clin Transl Hepatol
Ruan LM, Zhang XC, Zhang XY, Zhou QQ, Zheng QN, Fu CL, Hu YB, Zhou Y, Wu YH.   +8 more
europepmc   +1 more source

Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye. [PDF]

Turk J Gastroenterol
Gunduz A, Öztoprak NÇ, Sarı ND, Kurtaran B, Önlen Y, Senates E, Zerdali E, Karsen H, Batırel A, Ali RK, Güner R, Yamazhan T, Kose S, Erben N, Ince N, Köksal İ, Sarıgül Yıldırım F, Yoruk G, Komur S, Bal T, Kaya S, Esen Ş, Günal Ö, Yıldız IE, Inan D, Barut Ş, Namıduru M, Tosun S, Türker K, Sener A, Hızel K, Baykam N, Duygu F, Akıncı E, Can G, User U, Gül HC, Akbulut A, Çelebi G, Sünnetçioğlu M, Karabay O, Kumbasar Karaosmanoğlu H, Sırmatel F, Tabak F, Hep-C Turkey Study Group.   +44 more
europepmc   +1 more source

Short-Term Clinical and Immunologic Outcomes Conditional on SVR12 in Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis Treated With Direct-Acting Antivirals: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Boonpheng B, Ungprasert P.
europepmc   +1 more source

Safety and Drug-Drug Interaction Burden of Direct-Acting Antiviral Therapy for Hepatitis C: A Single-Center Community Hospital Analysis. [PDF]

Int J Hepatol
Okabe S, Doi A, Matsumoto K, Yamamoto M, Fukui K, Nishida T.   +5 more
europepmc   +1 more source